Bone Biologics (BBLGW) Debt to Equity (2016 - 2017)
Bone Biologics (BBLGW) has disclosed Debt to Equity for 2 consecutive years, with -$1.97 as the latest value for Q3 2017.
- Quarterly Debt to Equity rose 8.14% to -$1.97 in Q3 2017 from the year-ago period, while the trailing twelve-month figure was -$1.97 through Sep 2017, up 8.14% year-over-year, with the annual reading at -$1.05 for FY2016, N/A changed from the prior year.
- Debt to Equity for Q3 2017 was -$1.97 at Bone Biologics, roughly flat from -$1.97 in the prior quarter.
- The five-year high for Debt to Equity was -$1.05 in Q4 2016, with the low at -$4.44 in Q1 2016.